Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today. The company’s shares closed last ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by ...

MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving ...

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...